The content on this site is intended for healthcare professionals only
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Oct 2021
Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatmen...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
14 Oct 2021
Pathogenesis of colon adenocarcinoma in Kerala, India
Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center...
12 Oct 2021
Radioembolisation with chemotherapy for colorectal liver metastases
Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA
28 Sep 2021
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal c...
Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA
23 Sep 2021
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with ...
Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
20 Sep 2021
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) w...
Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
20 Sep 2021
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-l...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
18 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
Oesophageal and gastric cancers
Dr Mike Cusnir - Mount Sinai Medical Center, Florida, USA
28 Jul 2021
BEACON-CRC: first-line bevacizumab in colorectal cancer treatment
Prof Dan Aderka - Tel-Aviv University, Tel-Aviv, Israel
26 Jul 2021
